MYC and Familial prostate cancer: When the leading edge genes within the AFI-induced MYC_targets_V1 signature (Fig. 4b, Table 1 and Supplementary Data 11) were used to create a metagene score, we found that prostate cancer patients with greater AFI-dependent MYC transcriptional activation in their tumour tissues were more likely to die of their disease (n lethal = 31, Odds Ratio (OR) = 3.44, 95% CI = 1.69–7.38).